| ORIGINAL RESEARCH |
|
| Year : 2023 | Volume
: 15
| Issue : 4 | Page : 350-356 |
|
|
The effectiveness of an incremental approach to nonsurgical periodontal therapy with the use of adjunctive slow-release locally administered 0.02% hypochlorite formulation: A randomized clinical study
Simone Marconcini1, Saverio Cosola2, Enrica Giammarinaro2, Giacomo Oldoini1, Annamaria Genovesi3
1 Department of Oral Surgery, Istituto Stomatologico Toscano, Lido di Camaiore, Italy
2 Department of Oral Surgery, Università Vita Salute San Raffaele, Milano, Italy
3 Department of Oral Surgery, Istituto Stomatologico Toscano, Lido di Camaiore, Italy; Department of Oral Hygiene, Università Marconi, Lido di Camaiore, Italy
Correspondence Address:
Dr. Enrica Giammarinaro
Università Vita-Salute San Raffaele, Via Olgettina 60, 20132 Milano
Italy
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jioh.jioh_269_22
|
|
|
Aim: Bacterial plaque is associated with periodontal inflammation. The aim of this study was to prospectively assess the clinical effectiveness of two different agents in a staged approach for nonsurgical periodontal treatment in terms of clinical and patients related outcomes in a cohort of patients with periodontitis: NitrAdine®-based disinfectant formula (PerioTabs®) vs. Chlorhexidine (CHX) 0.12% toothpaste and mouthwash 0.20%. Materials and Methods: In the current randomized investigation, patients diagnosed with periodontal disease (stages I–III) scheduled for nonsurgical periodontal therapy were assigned at random to utilize PerioTabs®, a NitrAdine® brushing solution, or a CHX mouthwash at home. After 10–15 days of product use, active decontamination using sonic scalers and powders was carried out. The study’s outcomes were tracked at the beginning, throughout the professional intervention, and 30 and 90 days later. Assessments were made of clinical and patient-related factors. For the purposes of descriptive and inferential statistics, the chosen variables were entered into a virtual environment. Results: Forty patients were included in the final analysis. All patients showed major clinical and patient-related outcomes improvement after therapy at each time point. In the PerioTabs® group, the decrease in the bleeding score observed after the initial 10-day preparatory period (before active decontamination) was greater than in the CHX group, respectively, –45.17 ± 4.69% and –21.51 ± 2.07%. Conclusion: This study reported that the staged approach improved the clinical effectiveness of periodontal treatment in patients with periodontal disease and further suggests that PerioTabs® can be used as an efficient alternative to CHX as an adjunctive antimicrobial intervention prior to active decontamination. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
